Skip to content

EPIRUS Biopharmaceuticals, Inc.: financial reference

Explore EPIRUS Biopharmaceuticals, Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Filing record ends 2016-03-29

The latest filing in this captured record is a 10-K filed 2016-03-29. No later filing is in the SEC companyfacts record captured on 2026-09-22. EPIRUS Biopharmaceuticals, Inc. may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assets-2015-12-3172,264,000USD2016-03-29
Stockholders equity-2015-12-3136,368,000USD2016-03-29
Cash and cash equivalents-2015-12-3131,515,000USD2016-03-29
Net income or loss2015-01-012015-12-31-52,188,000USD2016-03-29
Operating cash flow2013-01-012013-12-31-29,735,000USD2014-03-14
Capital expenditure payments2015-01-012015-12-31477,000USD2016-03-29
Revenue2013-01-012013-12-3114,731,000USD2014-03-14
Financing cash flow2013-01-012013-12-3113,286,000USD2014-03-14
Investing cash flow2013-01-012013-12-3129,886,000USD2014-03-14
Retained earnings or deficit-2015-12-31-138,759,000USD2016-03-29
Basic weighted-average shares2011-01-012011-12-3197,347,193shares2012-03-09
Diluted weighted-average shares2011-01-012011-12-3197,347,193shares2012-03-09
Income tax expense or benefit2015-01-012015-12-31-544,000USD2016-03-29
Net property, plant and equipment-2015-12-312,073,000USD2016-03-29
Share-based compensation expense2015-01-012015-12-313,470,000USD2016-03-29
Operating income or loss2015-01-012015-12-31-52,300,000USD2016-03-29
Current assets-2015-12-3135,247,000USD2016-03-29
Interest expense2013-01-012013-12-311,467,000USD2014-03-14
Current liabilities-2015-12-3133,281,000USD2016-03-29
Current accounts payable-2015-12-312,051,000USD2016-03-29
Goodwill carrying amount-2015-12-3126,361,000USD2016-03-29
Net finite-lived intangible assets-2015-12-316,410,000USD2016-03-29
Net current accounts receivable-2013-12-312,511,000USD2014-03-14
Operating expenses2015-01-012015-12-3152,876,000USD2016-03-29
Research and development expense2015-01-012015-12-3130,925,000USD2016-03-29
Common shares outstanding-2015-12-3124,377,573shares2016-03-29
Accumulated other comprehensive income or loss-2015-12-31-23,000USD2016-03-29
Gross property, plant and equipment-2015-12-312,373,000USD2016-03-29
Accumulated depreciation on property, plant and equipment-2015-12-31300,000USD2016-03-29
Other noncurrent assets-2015-12-31249,000USD2016-03-29
Other noncurrent liabilities-2015-12-31425,000USD2016-03-29
Accrued current liabilities-2015-12-314,003,000USD2016-03-29
Prepaid expenses and other current assets-2015-12-313,732,000USD2016-03-29
Pre-tax income or loss from continuing operations2015-01-012015-12-31-52,732,000USD2016-03-29
Comprehensive income or loss2015-01-012015-12-31-52,211,000USD2016-03-29
General and administrative expense2015-01-012015-12-3121,951,000USD2016-03-29
Depreciation, depletion and amortization2013-01-012013-12-3110,048,000USD2014-03-14
Amortization of intangible assets2013-01-012013-12-318,722,000USD2014-03-14
Other nonoperating income or expense2015-01-012015-12-31-116,000USD2016-03-29
Nonoperating income or expense2015-01-012015-12-31-432,000USD2016-03-29
Proceeds from issuing common stock2015-01-012015-12-3147,962,000USD2016-03-29
Change in accounts receivable2013-01-012013-12-31-534,000USD2014-03-14
Change in accounts payable2015-01-012015-12-31-1,235,000USD2016-03-29

Filings

20 EPIRUS Biopharmaceuticals, filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
EPIRUS Biopharmaceuticals, Inc. / CIK 0001135906
Captured
SEC response SHA-256
87f8224528d5be267378d02137fa575d4041842bd702d7de7999c10c2349849b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001135906.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))